Jones Joyce, Taylor Barbara, Wilkin Timothy J, Hammer Scott M
Columbia University Medical Center, New York, NY, USA.
Top HIV Med. 2007 Apr-May;15(2):48-82.
The 14th Conference on Retroviruses and Opportunistic Infections provided a forum for presentation of state-of-the-art research on antiretroviral therapy. This year's conference marked the first public presentation of phase III trials of the lead compounds in 2 new drug classes: maraviroc (a CCR5 inhibitor) and raltegravir (an HIV-1 integrase inhibitor). These agents are likely to be approved by the US Food and Drug Administration this year and should provide major new options for treatment-experienced patients with multidrug resistant virus. Other dominant themes of the conference were the impressive number of presentations describing outcomes of antiretroviral therapy programs in resource-limited settings and new information on mechanisms of drug resistance. Among the latter, the importance of drug resistance mutations occurring in the RNase H and connection domains of the HIV-1 reverse transcriptase was of special note. In addition, substantial new information was presented on other new antiretroviral agents, studies in treatment-naive patients, antiretroviral therapy strategies, prevention of mother-to-child transmission, predictors of clinical response to therapy, and antiretroviral pharmacokinetics. Research in antiretroviral therapy remains dynamic and advances in the field continue to improve our ability to maintain long-term control of HIV-1 replication in infected persons.
第14届逆转录病毒与机会性感染会议为抗逆转录病毒疗法的前沿研究提供了一个展示平台。今年的会议首次公开了两类新药中先导化合物的III期试验结果：马拉维若（一种CCR5抑制剂）和雷特格韦（一种HIV-1整合酶抑制剂）。这些药物今年很可能会获得美国食品药品监督管理局的批准，为有多种药物耐药病毒感染经历的患者提供重要的新治疗选择。会议的其他主要议题包括：大量关于资源有限地区抗逆转录病毒治疗项目成果的报告，以及有关耐药机制的新信息。在后者中，HIV-1逆转录酶的核糖核酸酶H和连接结构域中出现的耐药突变的重要性尤其值得关注。此外，还展示了关于其他新型抗逆转录病毒药物、初治患者研究、抗逆转录病毒治疗策略、母婴传播预防、治疗临床反应预测指标以及抗逆转录病毒药代动力学的大量新信息。抗逆转录病毒疗法的研究依然活跃，该领域的进展不断提高我们在感染者中维持对HIV-1复制长期控制的能力。
